# Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Source: https://onco.cc/trials/nct05727176/  
OnCo record `nct05727176` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TAS-120 in biliary tract cancer, run by Taiho Oncology, Inc., now recruiting.

## Summary

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT05727176 by Taiho Oncology, Inc., with 120 participants planned, started 2023-07-05 and due to reach its primary completion in 2026-12. Interventions recorded: TAS-120.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05727176
- Phase: 2
- Setting: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
- Sponsor: Taiho Oncology, Inc.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT05727176: https://clinicaltrials.gov/study/NCT05727176

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct05727176.json